The American Joint Committee on Cancer (AJCC) 8th and 9th edition staging manuals now incorporate prognostic staging for breast cancer, where histologic grade remains a factor—alongside estrogen and progesterone receptor status, HER2 amplification, and select molecular assays—in assessing recurrence risk. Here, ERBB2 is linked to breast cancer.